AndreasNicholasSaltosMD

Thoracic Cancer

Associate Member, Department of Thoracic Oncology Clinical Research Medical Director, Department of Thoracic Oncology

Overview of Dr. Saltos

Dr. Andreas Saltos is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Maryland School of Medicine and has been in practice 8 years. He is one of 172 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 20 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(229) 597-2173

Education & Training

University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2015 - 2018
University of MarylandResidency, Internal Medicine, 2012 - 2015
University of Maryland School of MedicineClass of 2012

Certifications & Licensure

FL State Medical License 2015 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors Start of enrollment: 2016 Nov 23
Completed
Phase 1, Phase 2
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer Start of enrollment: 2018 Nov 29
ACTIVE_NOT_RECRUITING
PHASE2
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Start of enrollment: 2019 Feb 01
ACTIVE_NOT_RECRUITING
PHASE1
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Jul 25
ACTIVE_NOT_RECRUITING
PHASE2
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Start of enrollment: 2020 Nov 23
Terminated
Phase 1
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer Start of enrollment: 2022 Feb 23
Recruiting
Phase 1
CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC Start of enrollment: 2021 Mar 17
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01
Reply to: Osimertinib Plus Antiangiogenic Agents: A Promising New Paradigm With Uncertain Results.
Xiuning Le, Mike Hernandez, Simon Heeke, Andreas Saltos, John V Heymach
Journal of Clinical Oncology. 2025-02-24
3 citations
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung...
Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn
Journal of Clinical Oncology. 2025-02-01

Lectures

Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019